Autolus Therapeutics Inc. (NASDAQ: AUTL) stock declined by 6.12% at the last close whereas the AUTL stock price tends to rise by 5.09% in the after-hours trading session. Autolus is a biopharmaceutical firm in the clinical stages of developing next-generation programmable T cell treatments for cancer therapy.
AUTL stock’ Recent Development
Autolus Therapeutics reported that the company’s new production plant in Stevenage, UK, has received planning clearance. Merit Holdings Limited is serving as a general contractor for the Reef Group, which will lease the 70,000 square foot site to Autolus. The current clinical trial production plant at The Cell and Gene Therapy Catapult (CGTC) facility will first offer worldwide commercial launch capacity for obecabtagene autoleucel (obe-cel). The company will then relocate to the new Autolus facility, which will first have GMP capability for 2,000 batches per year with room to grow.
Dr. Christian Itin, CEO of Autolus said that Stevenage is quickly becoming one of Europe’s major biotechnology hubs. The development of their own production plant, on the other hand, would ensure obe-cel’s international commercial launch capabilities. They’re thrilled about the progress they’ve made with obe-cel for the therapy in patients with acute lymphoblastic leukaemia (ALL), and they’re anticipating results from the pivotal FELIX trial in 2022.
John H. Johnson has been chosen as non-executive chairman of Autolus Therapeutics plc’s Board of Directors, from September 15, 2021. Dr. Martin Murphy, who was formerly chairman, will remain on the Board as a non-executive member.
Mr. Johnson has more than 30 years of expertise in the life sciences sector, which is great for Autolus. Before being appointed at Autolus he was working as the CEO and a director of Strongbridge Biopharma plc, which is a commercial stage pharmaceutical company registered on the NASDAQ. Also, He has performed executive, operational, and commercial leadership positions at Eli Lilly & Company, ImClone, Johnson & Johnson, and Pfizer in the pharmaceuticals sector.